Equities researchers at MLV Capital boosted their target price on shares of Zalicus (NASDAQ: ZLCS)
Zalicus traded up 7.62% on Thursday, hitting $0.6995. Zalicus has a 52-week low of $0.43 and a 52-week high of $1.62. The stock?s 50-day moving average is currently $0.68. The company?s market cap is $88.5 million.
Zalicus last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $3.67 million for the quarter, compared to the consensus estimate of $3.12 million. On average, analysts predict that Zalicus will post $-0.29 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a ?neutral? rating on shares of Zalicus in a research note to investors on Wednesday. They now have a $1.00 price target on the stock. Separately, analysts at Oppenheimer reiterated an ?outperform? rating on shares of Zalicus in a research note to investors on Wednesday. They now have a $2.00 price target on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of Zalicus in a research note to investors on Thursday, January 3rd. They set a ?neutral? rating on the stock.
Two equities research analysts have rated the stock with a buy rating, and one has given a hold rating to the company?s stock. The stock currently has an average rating of ?overweight? and a consensus target price of $2.00.
Zalicus Inc., formerly CombinatoRx, Incorporated, is a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain and inflammation.